Table 2.
Incremental cost-effectiveness ratios of ERT in IOPD including inflation and currency adjustment
| Author, year | Currency | Country | Treatment (Myozyme) | ICER | Inflation-adjusted from data year to 2017a | Currency and inflation-adjusted (2017 USD)a |
|---|---|---|---|---|---|---|
| Kanters et al. (2014) [30] | 2009 euros | Netherlands | 40 mg/kg/week | €1,043,868 per QALY gained | €1,174,210 | $1,323,207 |
| Kanters et al. (2014) [30] | 2009 euros | Netherlands | 20 mg/kg/2 week | €286,114 per QALY gained | € 321,840 | $362,678 |
| Castro-Jaramillo (2012) [29] | 2010 GBP | England | 20 mg/kg/2 week | £234,308 per QALY gained | £269,674 | $347,070 |
| Castro-Jaramillo (2012) [29] | 2010 GBP | Columbia | 20 mg/kg/2 week | £109,991 per QALY gained | £145,183 | $186,851 |
CPI consumer price index, ERT enzyme-replacement therapy, GBP Great Britain pounds, ICER incremental cost-effectiveness ratio, IOPD infantile-onset Pompe disease, OECD Organisation for Economic Cooperation and Development, QALY quality-adjusted life year, USD United States dollars
aInflation-adjusted from data to year 2017 (inflation-adjusted to 2017 using average annual inflation rate per year reported by the OECD for each country and inflated based on data year). OECD (2018), “Inflation consumer price index (CPI) (indicator).” 10.1787/eee82e6e-en (accessed on 17 July 2018). Inflation-adjusted currency converted to USD based on currency reported in the publication. OECD (2018), “Exchange rates (indicator).” 10.1787/037ed317-en (accessed on 17 July 2018)